King's College Hospital NHS, Fetal Medicine Foundation
London, SE5 9RS, United Kingdom
NCT Number: NCT05326191
An observational cohort study to assess the clinical utility of the OxNNet Toolkit for the prediction of adverse pregnancy outcomes.
Looking for future studies?
Notify Me18 year and older
Female
Observational
London, SE5 9RS, United Kingdom
The First PLUS study is a single centre, prospective, observational study recruiting 4000 women from The Harris Birthright Centre, which provides ultrasound scanning for all women who would attend King's College Hospital NHS Foundation Trust for their pregnancy care.
This study aims to develop a tool to provide reliable measurements of placental size and estimate the blood flow within the placenta during the first trimester of pregnancy. These metrics hope to develop a screening tool for fetal growth restriction (FGR), which is a condition in which a baby fails to grow to its full potential and can cause adverse pregnancy outcomes and is the single most common cause of stillbirth. This devastating outcome could potentially be reduced by stratifying pregnancies into high risk, allowing women to undergo additional monitoring and limiting clinician resource to those in need of it most. Stillbirth is also a serious adverse pregnancy outcome that NHS England is looking to reduce the rate of as part of their long-term plan.
Women 18 years of age or older, attending their first trimester scan during 11-14 weeks of pregnancy, who has a viable pregnancy with no more than one baby with no major defects identified during the scan will be eligible to take part.
The study will take place over 24 months and participants will undergo a single study visit in which their demographics and routine medical history will be recorded, an additional research ultrasound scan will be conducted alongside their routine scan, and blood from a sample taken as part of routine care will be used to assess the level of Placental Growth Factor (PlGF). Participants will then be followed up until the completion of their pregnancy via their pregnancy records (remote follow up) and the outcome of their pregnancy will be recorded.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
All study interventions/procedures will happen during the participants routine clinic visit in which they will receive their routine Ultrasound scan, followed by an additional research scan, which will take approximately 2-3 minutes. A blood sample will also be taken from participants as part of their routine pregnancy care. Residual blood from the same sample will be used to conduct an additional test to quantify Placental Growth Factor (PlGF). Participants will also be asked questions about their relevant medical history and demographic data which is also routinely collected as part of their pregnancy record.
Time frame: 24 months
Fetal Growth restriction (FGR) defined according to the ISUOG Delphi consensus guidelines for diagnosis of FGR, at the time of delivery.
Time frame: 24 months
Defined if <10 centile on population-based centiles or <10th centile on customised centiles, at the time of delivery.
Time frame: 24 months
Defined by the ACOG guidelines for hypertensive disorders of pregnancy:
Time frame: 24 months
Defined by the ACOG guidelines for hypertensive disorders of pregnancy:
Time frame: 24 months
Defined by the ACOG guidelines for hypertensive disorders of pregnancy:
Time frame: 24 months
Defined by the ACOG guidelines for hypertensive disorders of pregnancy(22)
Time frame: 24 months
Defined as fasting plasma glucose level ≥5.6 mmol/L and/or 2-h plasma glucose level ≥7.8 mmol/L after ingestion of 75g oral glucose.
Time frame: 24 months
Birth ≥24+0 weeks <37+0 weeks
Time frame: 24 months
Live fetus at the first-trimester ultrasound scan but subsequent in utero fetal death or delivery <24+0 weeks
Time frame: 24 months
Baby born with no signs of life at ≥24+0 weeks' gestation
Time frame: 24 months
Baby born alive but dies within the first 28 days of life
Time frame: 24 months
Perspectum
Industry
First-trimester Placental Ultrasound Study (First PLUS): an Observational Cohort Study to Assess the Clinical Utility of the OxNNet Toolkit for the Prediction of Adverse Pregnancy Outcomes.
Acronym: First PLUS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06039319
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases and Pregnancy Complications
Knoxville, Tennessee, United States
View Trial DetailsNCT04536753
Fetal Growth Complications, Induction of Labor Affected Fetus / Newborn
Newcastle upon Tyne, Tyne and Wear, United Kingdom
View Trial DetailsNCT04060667
Death, Female Urogenital Diseases and Pregnancy Complications
Mbarara, Uganda
View Trial DetailsNCT07719335
Female Urogenital Diseases and Pregnancy Complications, Pregnancy Complications
Banī Suwayf, Egypt
View Trial Details